An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
NCT04130997Phase 3Active, not recruiting
- Lead sponsor
- TG Therapeutics, Inc. (Industry)
- Enrollment
- 1,100 (estimated)
- Start date
- 18 Nov 2019
- Primary completion
- 31 May 2032 (estimated)
- Study completion
- 31 May 2032
- Last update posted
- 30 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None
- Arms
- 1
Interventions
- Ublituximab Biological
Conditions and primary outcome
- Relapsing Multiple Sclerosis (RMS)
Primary outcome
Annualized Relapse Rate (ARR) (Up to Week 336)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
1 on PubMedFive Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.
JAMA neurology · 2026 Apr 1
PubMed 41697690 (opens in a new tab)DOI 10.1001/jamaneurol.2026.0007 (opens in a new tab)
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT04130997 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.